Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...

The 24-year study of more than 1.2 million children in Denmark found that aluminum exposure didn't raise the risk of autism, asthma, or other chronic diseases. Other science and research news is on ...

Researchers at Case Western Reserve University have discovered that the popular diabetes and weight-loss drug Ozempic may lower a person’s risk of developing dementia. The active ingredient in ...

A new study found that semaglutides like Ozempic are linked to a lower risk of Alzheimer's disease and dementia. Below, a neurologist explains the connection.

Popular diabetes and weight loss drug, semaglutide- the active ingredient in 'Wegovy' and 'Ozempic'- may lower dementia risk in people with type 2 diabetes. The corresponding study was published in ...

Neuroscientist Sabina Brennan encourages caregivers to live in the moment and notice the happy experiences they share with ...

Many breast cancer survivors experience cognitive impairment, difficulty concentrating, or memory loss during and after treatment. Despite the recognized link between mental cognition and breast ...

GLP-1 drugs may reduce asthma symptoms in obese adults, offering a steroid-free alternative to treatment. The study includes ...

The Dementia Risk Reduction Library draws heavily from Dr. Darrow’s Amazon best-selling books, Preventing Decline: Advances in the Medical Treatment of Hearing Loss and Tinnitus and Stop Living ...